These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. Evaluation of a novel PET tracer [ Wu M; Ren C; Mao C; Dong L; Li B; Yang X; Huang Z; Zhang H; Li Y; Yan M; Ge Q; Wu R; Feng F; Cui M; Gao J; Huo L Neuroimage; 2024 Sep; 298():120779. PubMed ID: 39122059 [TBL] [Abstract][Full Text] [Related]
45. Synthesis and evaluation of a (18)F-curcumin derivate for β-amyloid plaque imaging. Rokka J; Snellman A; Zona C; La Ferla B; Nicotra F; Salmona M; Forloni G; Haaparanta-Solin M; Rinne JO; Solin O Bioorg Med Chem; 2014 May; 22(9):2753-62. PubMed ID: 24702859 [TBL] [Abstract][Full Text] [Related]
46. Amyloid imaging in Alzheimer's disease: comparison of florbetapir and Pittsburgh compound-B positron emission tomography. Wolk DA; Zhang Z; Boudhar S; Clark CM; Pontecorvo MJ; Arnold SE J Neurol Neurosurg Psychiatry; 2012 Sep; 83(9):923-6. PubMed ID: 22791901 [TBL] [Abstract][Full Text] [Related]
47. F-18 Polyethyleneglycol stilbenes as PET imaging agents targeting Abeta aggregates in the brain. Zhang W; Oya S; Kung MP; Hou C; Maier DL; Kung HF Nucl Med Biol; 2005 Nov; 32(8):799-809. PubMed ID: 16253804 [TBL] [Abstract][Full Text] [Related]
48. Use of the PET ligand florbetapir for in vivo imaging of pancreatic islet amyloid deposits in hIAPP transgenic mice. Templin AT; Meier DT; Willard JR; Wolden-Hanson T; Conway K; Lin YG; Gillespie PJ; Bokvist KB; Attardo G; Kahn SE; Scheuner D; Hull RL Diabetologia; 2018 Oct; 61(10):2215-2224. PubMed ID: 30046852 [TBL] [Abstract][Full Text] [Related]
49. Optimization of automated radiosynthesis of [18F]AV-45: a new PET imaging agent for Alzheimer's disease. Liu Y; Zhu L; Plössl K; Choi SR; Qiao H; Sun X; Li S; Zha Z; Kung HF Nucl Med Biol; 2010 Nov; 37(8):917-25. PubMed ID: 21055622 [TBL] [Abstract][Full Text] [Related]
50. Nonlinear Association Between Cerebrospinal Fluid and Florbetapir F-18 β-Amyloid Measures Across the Spectrum of Alzheimer Disease. Toledo JB; Bjerke M; Da X; Landau SM; Foster NL; Jagust W; Jack C; Weiner M; Davatzikos C; Shaw LM; Trojanowski JQ; JAMA Neurol; 2015 May; 72(5):571-81. PubMed ID: 25822737 [TBL] [Abstract][Full Text] [Related]
51. Repeatability of parametric methods for [ Verfaillie SC; Golla SS; Timmers T; Tuncel H; van der Weijden CW; Schober P; Schuit RC; van der Flier WM; Windhorst AD; Lammertsma AA; van Berckel BN; Boellaard R J Cereb Blood Flow Metab; 2021 Mar; 41(3):569-578. PubMed ID: 32321347 [TBL] [Abstract][Full Text] [Related]
52. AZD2184: a radioligand for sensitive detection of beta-amyloid deposits. Johnson AE; Jeppsson F; Sandell J; Wensbo D; Neelissen JA; Juréus A; Ström P; Norman H; Farde L; Svensson SP J Neurochem; 2009 Mar; 108(5):1177-86. PubMed ID: 19141073 [TBL] [Abstract][Full Text] [Related]
53. Evaluation of Small-Animal PET Outcome Measures to Detect Disease Modification Induced by BACE Inhibition in a Transgenic Mouse Model of Alzheimer Disease. Deleye S; Waldron AM; Verhaeghe J; Bottelbergs A; Wyffels L; Van Broeck B; Langlois X; Schmidt M; Stroobants S; Staelens S J Nucl Med; 2017 Dec; 58(12):1977-1983. PubMed ID: 28611242 [TBL] [Abstract][Full Text] [Related]
54. Current status of PET-imaging probes of β-amyloid plaques. Koo J; Byun Y Arch Pharm Res; 2013 Oct; 36(10):1178-84. PubMed ID: 23812777 [TBL] [Abstract][Full Text] [Related]
55. Clinical impact of amyloid PET using Matsuda H; Okita K; Motoi Y; Mizuno T; Ikeda M; Sanjo N; Murakami K; Kambe T; Takayama T; Yamada K; Suehiro T; Matsunaga K; Yokota T; Tateishi U; Shigemoto Y; Kimura Y; Chiba E; Kawashima T; Tomo Y; Tachimori H; Kimura Y; Sato N Ann Nucl Med; 2022 Dec; 36(12):1039-1049. PubMed ID: 36194355 [TBL] [Abstract][Full Text] [Related]
56. Assessment of the Incremental Diagnostic Value of Florbetapir F 18 Imaging in Patients With Cognitive Impairment: The Incremental Diagnostic Value of Amyloid PET With [18F]-Florbetapir (INDIA-FBP) Study. Boccardi M; Altomare D; Ferrari C; Festari C; Guerra UP; Paghera B; Pizzocaro C; Lussignoli G; Geroldi C; Zanetti O; Cotelli MS; Turla M; Borroni B; Rozzini L; Mirabile D; Defanti C; Gennuso M; Prelle A; Gentile S; Morandi A; Vollaro S; Volta GD; Bianchetti A; Conti MZ; Cappuccio M; Carbone P; Bellandi D; Abruzzi L; Bettoni L; Villani D; Raimondi MC; Lanari A; Ciccone A; Facchi E; Di Fazio I; Rozzini R; Boffelli S; Manzoni L; Salvi GP; Cavaliere S; Belotti G; Avanzi S; Pasqualetti P; Muscio C; Padovani A; Frisoni GB; JAMA Neurol; 2016 Dec; 73(12):1417-1424. PubMed ID: 27802513 [TBL] [Abstract][Full Text] [Related]
57. Conversion of iodine to fluorine-18 based on iodinated chalcone and evaluation for β-amyloid PET imaging. Kaide S; Ono M; Watanabe H; Shimizu Y; Nakamoto Y; Togashi K; Yamaguchi A; Hanaoka H; Saji H Bioorg Med Chem; 2018 Jul; 26(12):3352-3358. PubMed ID: 29751990 [TBL] [Abstract][Full Text] [Related]
58. Amyloid PET Imaging: Standard Procedures and Semiquantification. D'Amico F; Sofia L; Bauckneht M; Morbelli S Methods Mol Biol; 2024; 2785():165-175. PubMed ID: 38427194 [TBL] [Abstract][Full Text] [Related]
59. A dual fluorinated and iodinated radiotracer for PET and SPECT imaging of β-amyloid plaques in the brain. Watanabe H; Ono M; Kimura H; Kagawa S; Nishii R; Fuchigami T; Haratake M; Nakayama M; Saji H Bioorg Med Chem Lett; 2011 Nov; 21(21):6519-22. PubMed ID: 21920750 [TBL] [Abstract][Full Text] [Related]
60. Impact of ¹⁸F-florbetapir PET imaging of β-amyloid neuritic plaque density on clinical decision-making. Zannas AS; Doraiswamy PM; Shpanskaya KS; Murphy KR; Petrella JR; Burke JR; Wong TZ Neurocase; 2014 Aug; 20(4):466-73. PubMed ID: 23672654 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]